Novo Nordisk opens NovoCare Pharmacy, selling Wegovy at $499 a month

Novo Nordisk opened NovoCare Pharmacy on March 5, 2025, a direct-to-patient service that ships all doses of Wegovy (semaglutide) to patients' homes for $499 a month when they pay cash ^[3][4].

The offer covers the five Wegovy injection dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg ^[3][4]. The $499 price is for a 28-day supply, and the same price applies at every dose, so patients do not pay more as their dose increases ^[3][4]. A prescription must come from a licensed health care professional, and the shipments are dispensed through CenterWell Pharmacy, a home-delivery pharmacy that is part of Humana ^[3][4]. NovoCare also provides benefit verification, refill reminders and access to a case manager ^[3].

Novo Nordisk said the program is aimed at uninsured patients or patients with commercial insurance that does not cover obesity medicines ^[3]. People enrolled in Medicare, Medicaid or any other federal or state health program are not eligible, and NovoCare does not accept commercial insurance ^[4]. The company says more than 55 million people in the United States have coverage specifically for weight-management medicines, and that 90% of Wegovy patients who have coverage pay $0 to $25 a month ^[3]. "With NovoCare Pharmacy, patients and prescribers alike have another option that provides convenient access to all doses of real, FDA-approved Wegovy at a reduced cost in our high-quality pen," said Dave Moore, executive vice president for U.S. operations and president of Novo Nordisk Inc. ^[3].

Before the launch, patients without insurance coverage for Wegovy could use a savings card that lowered the cost to $650 a month, according to the company's website ^[4]. Two clinicians who reviewed the program told Healio the new price is still high for many people. "It's definitely a lot of money, so I don't know what the uptake will be," said Diana Isaacs, a pharmacy specialist at Cleveland Clinic. "I'm sure [uptake] will be better than when it was $650. But it's still pretty expensive" ^[4]. Katherine Saunders, an obesity physician at Weill Cornell Medicine, said the price remains "out of reach" for most patients without insurance coverage, and that other barriers include insurance coverage, the number of qualified clinicians, and weight bias and stigma ^[4].

NovoCare's launch came less than two weeks after the FDA removed all doses of semaglutide from its drug shortage list ^[4]. Under that change, state-licensed compounding pharmacies could no longer distribute compounded semaglutide after April 22, 2025, and outsourcing facilities had to stop making it after May 22, 2025 ^[4]. Novo Nordisk says its program offers FDA-approved Wegovy rather than compounded "semaglutide," which the company and regulators have warned can pose risks ^[3][4].

Why it matters for patients

The $499 price is a cash-pay price. It does not run through insurance, so it does not count toward a deductible or out-of-pocket maximum in the way a covered prescription would, and patients with commercial insurance cannot use NovoCare to fill a covered prescription ^[4]. People covered by Medicare or Medicaid cannot use the program at all ^[4].

For patients who do have coverage for obesity medicines, the company says the typical cost is far lower, between $0 and $25 a month, so paying cash is generally the more expensive path ^[3]. For patients without coverage, $499 a month is a large cut from the $1,349 list price but still a recurring monthly expense, and the two clinicians who reviewed the program said that gap likely leaves the drug unaffordable for many ^[4].

Getting a prescription works differently than with some competing programs. A Novo Nordisk spokesperson said NovoCare is only for patients prescribed Wegovy and is not partnered with any health care practices or telehealth companies, while Eli Lilly's LillyDirect works with several telehealth providers to connect patients with a clinician ^[4]. Patients who do not already have a prescriber would need to arrange that separately; NovoCare's terms and conditions say the program is cash-pay only ^[4].

What happens next

Novo Nordisk said the overall savings offer for Wegovy will be updated "in the near future" so that cash-paying patients who use traditional retail pharmacies also get the lower price ^[3]. No date for that change was given ^[3].

On the insurance side, CVS Caremark, described as the country's largest pharmacy benefit manager, selected Wegovy as the preferred GLP-1 medicine covered for obesity on its largest commercial template formularies, effective July 1 ^[2].

The two compounding deadlines tied to the shortage resolution fell on April 22 and May 22, 2025 ^[4].

It has not been reported how many patients have enrolled in NovoCare Pharmacy or how the program has changed the price patients actually pay.